Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

James P. Thomas MD, PhD

James P. Thomas MD, PhD


Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Hematology

Member of the Cancer Center


  • PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue (Thomas JP, Geiger PG) Cancer Res Thomas JP, Geiger PG. Abstract 4443: PB-42: Design and characterization of a glutathione pro-drug selectively delivered to normal tissue and not tumor tissue. Cancer Res. August 1, 2015 75; 4443. 08/01/2015
  • Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. (Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC) Cancer Biol Ther 2015;16(5):764-9 PMID: 25778705 PMCID: PMC4622996 03/18/2015
  • Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. (Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T) Ann Surg Oncol 2015 Oct;22(11):3716-23 PMID: 25777092 03/18/2015
  • Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 PMID: 25123702 PMCID: PMC4299387 08/16/2014
  • Molecular profiling in gastric cancer: examining potential targets for chemotherapy. (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC) J Surg Oncol 2014 Sep;110(3):302-6 PMID: 24844210 05/23/2014
  • Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. (Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK) Eur J Cancer 2014 Jul;50(10):1747-57 PMID: 24767470 04/29/2014
  • Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK) Surg Endosc 2014 May;28(5):1505-14 PMID: 24687416 04/02/2014
  • Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 PMID: 24569947 PMCID: PMC3958454 02/27/2014
  • Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. (Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW) Case Rep Endocrinol 2013;2013:675298 PMID: 24455332 PMCID: PMC3881387 01/24/2014
  • Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. (Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK) Ann Surg Oncol 2014 Jan;21(1):240-7 PMID: 24114054 10/12/2013
  • Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. (Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) Exp Ther Med 2011 1;2(1):119-123 PMID: 21373381 PMCID: PMC3046871 03/05/2011
  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. (Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL) Clin Colorectal Cancer 2010 Jul;9(3):157-61 PMID: 20643620 PMCID: PMC3058720 07/21/2010
  • The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. (Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD) Cancer Chemother Pharmacol 2010 Oct;66(5):973-80 PMID: 20127092 PMCID: PMC2921466 02/04/2010
  • Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. (Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH) Invest New Drugs 2011 Apr;29(2):316-22 PMID: 19997959 PMCID: PMC3038176 12/10/2009
  • NCCN Clinical Practice Guidelines in Oncology: colon cancer. (Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, National Comprehensive Cancer Network) J Natl Compr Canc Netw 2009 Sep;7(8):778-831 PMID: 19755046 09/17/2009
  • Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. (Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA) Cancer J 2009 Jul-Aug;15(4):339-43 PMID: 19672152 08/13/2009
  • Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. (Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS) Oncology 2009;76(5):333-7 PMID: 19307739 03/25/2009
  • A phase I study of an oral simulated FOLFOX with high dose capecitabine. (Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G) Invest New Drugs 2009 Oct;27(5):461-8 PMID: 19129971 PMCID: PMC2899673 01/09/2009
  • Association of family history with cancer recurrence and survival among patients with stage III colon cancer. (Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS) JAMA 2008 Jun 4;299(21):2515-23 PMID: 18523220 PMCID: PMC3616330 06/05/2008
  • A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. (LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J) Cancer Chemother Pharmacol 2008 Dec;63(1):109-15 PMID: 18322686 03/07/2008
  • Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. (Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S) Clin Adv Hematol Oncol 2008 Jan;6(1):44-54 PMID: 18322441 03/07/2008
  • A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. (Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G) Cancer Chemother Pharmacol 2008 Sep;62(4):727-33 PMID: 18172649 01/04/2008
  • Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. (Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE) J Inorg Biochem 2008 Apr;102(4):693-8 PMID: 18061679 PMCID: PMC2390869 12/07/2007
  • Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ) J Clin Oncol 2007 Aug 10;25(23):3456-61 PMID: 17687149 08/10/2007
  • Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. (Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G) Clin Cancer Res 2007 Jun 15;13(12):3623-9 PMID: 17510207 05/19/2007
  • Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D) Int J Radiat Oncol Biol Phys 2007 May 1;68(1):13-23 PMID: 17448867 04/24/2007
  • Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. (McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G) Clin Cancer Res 2005 Nov 1;11(21):7851-60 PMID: 16278408 11/10/2005
  • A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. (Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP) Oncology 2005;69(2):130-4 PMID: 16118509 08/25/2005
  • A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. (Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA) Clin Cancer Res 2005 May 1;11(9):3410-6 PMID: 15867242 05/04/2005
  • Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. (Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson AB 3rd) Oncology 2004;66(4):303-9 PMID: 15218298 06/26/2004
  • Gemcitabine, Paclitaxel, and piritrexim: a phase I study. (Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP) Am J Clin Oncol 2003 Jun;26(3):280-4 PMID: 12796601 06/11/2003
  • Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. (Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP) Int J Gastrointest Cancer 2002;32(2-3):125-8 PMID: 12794248 06/10/2003
  • Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. (Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G) J Clin Oncol 2003 Jan 15;21(2):223-31 PMID: 12525513 01/15/2003
  • Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72 PMID: 12451473 11/27/2002
  • Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. (Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G) Invest New Drugs 2002 Nov;20(4):377-82 PMID: 12448654 11/27/2002
  • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. (Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd) J Clin Oncol 2002 Aug 1;20(15):3270-5 PMID: 12149301 08/01/2002
  • Phase I clinical and pharmacokinetic trial of irofulven. (Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H) Cancer Chemother Pharmacol 2001 Dec;48(6):467-72 PMID: 11800027 01/22/2002
  • Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. (Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D) Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):657-61 PMID: 11401916 06/13/2001
  • Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. (Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK) Ann Oncol 2000 Oct;11(10):1313-22 PMID: 11106122 12/06/2000
  • Nitric oxide donor compounds inhibit the toxicity of oxidized low-density lipoprotein to endothelial cells. (Struck AT, Hogg N, Thomas JP, Kalyanaraman B) FEBS Lett 1995 Mar 20;361(2-3):291-4 PMID: 7698340 03/20/1995
  • Involvement of preexisting lipid hydroperoxides in Cu(2+)-stimulated oxidation of low-density lipoprotein. (Thomas JP, Kalyanaraman B, Girotti AW) Arch Biochem Biophys 1994 Dec;315(2):244-54 PMID: 7986064 12/01/1994
  • The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. (Whelan HT, Schmidt MH, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, Thomas JP, Meyer GA) J Neurosurg 1993 Oct;79(4):562-8 PMID: 8410226 10/01/1993
  • Hyperexpression of catalase in selenium-deprived murine L1210 cells. (Lin F, Thomas JP, Girotti AW) Arch Biochem Biophys 1993 Aug 15;305(1):176-85 PMID: 8342949 08/15/1993
  • Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. (Thomas JP, Geiger PG, Girotti AW) J Lipid Res 1993 Mar;34(3):479-90 PMID: 8468531 03/01/1993
  • Intracellular catalase inhibition does not predispose rat heart to ischemia-reperfusion and hydrogen peroxide-induced injuries. (Konorev EA, Struck AT, Baker JE, Ramanujam S, Thomas JP, Radi R, Kalyanaraman B) Free Radic Res Commun 1993;19(6):397-407 PMID: 8168729 01/01/1993
  • Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. (Geiger PG, Thomas JP, Girotti AW) Arch Biochem Biophys 1991 Aug 1;288(2):671-80 PMID: 1898056 08/01/1991
  • Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. (Maiorino M, Thomas JP, Girotti AW, Ursini F) Free Radic Res Commun 1991;12-13 Pt 1:131-5 PMID: 2071029 01/01/1991
  • Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. (Thomas JP, Geiger PG, Maiorino M, Ursini F, Girotti AW) Biochim Biophys Acta 1990 Aug 6;1045(3):252-60 PMID: 2386798 08/06/1990
  • Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. (Thomas JP, Maiorino M, Ursini F, Girotti AW) J Biol Chem 1990 Jan 5;265(1):454-61 PMID: 2294113 01/05/1990
  • Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. (Thomas JP, Girotti AW) Cancer Res 1989 Apr 1;49(7):1682-6 PMID: 2522345 04/01/1989
  • Glucose administration augments in vivo uptake and phototoxicity of the tumor-localizing fraction of hematoporphyrin derivative. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Mar;49(3):241-7 PMID: 2525259 03/01/1989
  • Reactivity of photochemically-generated lipid hydroperoxides in cell membranes with glutathione peroxidase. (Thomas JP, Girotti AW) Photochem Photobiol 1989 Feb;49(2):153-6 PMID: 2523541 02/01/1989
  • Photooxidation of cell membranes in the presence of hematoporphyrin derivative: reactivity of phospholipid and cholesterol hydroperoxides with glutathione peroxidase. (Thomas JP, Girotti AW) Biochim Biophys Acta 1988 Oct 14;962(3):297-307 PMID: 2971397 10/14/1988
  • Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism. (Bachowski GJ, Thomas JP, Girotti AW) Lipids 1988 Jun;23(6):580-6 PMID: 3172988 06/01/1988
  • Beneficial effects of iloprost in the stunned canine myocardium. (Farber NE, Pieper GM, Thomas JP, Gross GJ) Circ Res 1988 Feb;62(2):204-15 PMID: 2448057 02/01/1988
  • Singlet oxygen intermediacy in the photodynamic action of membrane-bound hematoporphyrin derivative. (Thomas JP, Hall RD, Girotti AW) Cancer Lett 1987 Jun;35(3):295-302 PMID: 2954632 06/01/1987
  • Photodynamic action of merocyanine 540 on artificial and natural cell membranes: involvement of singlet molecular oxygen. (Kalyanaraman B, Feix JB, Sieber F, Thomas JP, Girotti AW) Proc Natl Acad Sci U S A 1987 May;84(9):2999-3003 PMID: 3033673 PMCID: PMC304788 05/01/1987
  • Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins. (Thomas JP, Bachowski GJ, Girotti AW) Biochim Biophys Acta 1986 Dec 10;884(3):448-61 PMID: 3778934 12/10/1986
  • Xanthine oxidase-catalyzed crosslinking of cell membrane proteins. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1986 Dec;251(2):639-53 PMID: 3800391 12/01/1986
  • Prooxidant and antioxidant effects of ascorbate on photosensitized peroxidation of lipids in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) Photochem Photobiol 1985 Mar;41(3):267-76 PMID: 4011692 03/01/1985
  • Inhibitory effect of zinc(II) on free radical lipid peroxidation in erythrocyte membranes. (Girotti AW, Thomas JP, Jordan JE) J Free Radic Biol Med 1985;1(5-6):395-401 PMID: 3841804 01/01/1985
  • Lipid photooxidation in erythrocyte ghosts: sensitization of the membranes toward ascorbate- and superoxide-induced peroxidation and lysis. (Girotti AW, Thomas JP, Jordan JE) Arch Biochem Biophys 1985 Jan;236(1):238-51 PMID: 2981506 01/01/1985
  • Damaging effects of oxygen radicals on resealed erythrocyte ghosts. (Girotti AW, Thomas JP) J Biol Chem 1984 Feb 10;259(3):1744-52 PMID: 6546380 02/10/1984
  • Superoxide and hydrogen peroxide-dependent lipid peroxidation in intact and triton-dispersed erythrocyte membranes. (Girotti AW, Thomas JP) Biochem Biophys Res Commun 1984 Jan 30;118(2):474-80 PMID: 6322749 01/30/1984
  • Last update: 09/23/2015